AAV-AAV6.2FF Rep-Cap plasmid (serotype AAV6.2FF - specific AAV RC-AAV6.2FF plasmids) (Amp and Kanamycin) (GeneMedi Owned)

GeneMedi's AAV6.2FF Rep-Cap plasmid supplies the AAV2 Rep (replication) proteins and the AAV6.2FF capsid protein.

You can produce AAV6.2FF particle in 293T cell line in high titer using GeneMedi's AAV6.2FF Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.

The tissue tropism of the AAV6.2FF vector has been validated in the lung, muscles, and airways, with potential applications in tissue-specific gene therapy.

GeneMedi offers both Ampicillin (Amp) resistance and Kanamycin (Kan) resistance for the AAV Rep-Cap Plasmids.

Target products collectionGo to AAV vector system >>


Product Description

Cat.NO Product Name Organization Type Price(In USD)
P-RC29 AAV6.2FF Rep-Cap Plasmid (Amp resistance)
Size:5ug
Academic 2062
P-RC29 AAV6.2FF Rep-Cap Plasmid (Amp resistance)
Size:5ug
Industry R&D
(excluding
CRO&CDMO&CXO)
P-RC29 AAV6.2FF Rep-Cap Plasmid (Amp resistance)
Size:5ug
CRO&CDMO&
CXO&CMC&
Manufacturing company
P-RC29 AAV6.2FF Rep-Cap Plasmid (Amp resistance)
Size:≥10mg
All
P-RC29-Kan AAV6.2FF Rep-Cap Plasmid (Kan resistance)
Size:≥10mg
All
P-PK29 AAV6.2FF Vector System (Amp resistance)
1. AAV6.2FF Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
Academic 3379
P-PK29 AAV6.2FF Vector System (Amp resistance)
1. AAV6.2FF Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
Industry R&D
(excluding
CRO&CDMO&CXO)
P-PK29 AAV6.2FF Vector System (Amp resistance)
1. AAV6.2FF Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
CRO&CDMO&
CXO&CMC&
Manufacturing company
P-PK29 AAV6.2FF Vector System (Amp resistance)
1. AAV6.2FF Rep-Cap Plasmid, ≥10mg
2. AAV Helper Plasmid, ≥10mg
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01-Kan), ≥10mg
All
P-PK29-Kan AAV6.2FF Vector System(Kan resistance)
1. AAV6.2FF Rep-Cap Plasmid(Kan resistance), ≥10mg
2. AAV Helper Plasmid(Kan resistance), ≥10mg
3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), ≥10mg
All
GeneMedi offers both seed and amplification services for the Amp-resistant AAV Rep-Cap Plasmid.
GeneMedi only offers amplification services and do not provide seed for the Kan-resistant AAV Rep-Cap Plasmid currently.
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.
Terms of sale:
For Seed (5ug):
The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party.

For plasmid production& amplification (≥10mg):
The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party.

Citation

Title Publication Date
FARS2 Deficiency Causes Cardiomyopathy by Disrupting Mitochondrial Homeostasis and the Mitochondrial Quality Control System Circulation 2024/2/16
Hepatic cytochrome P450 8B1 and cholic acid potentiate intestinal epithelial injury in colitis by suppressing intestinal stem cell renewal Cell Stem Cell 2022/9/1
Significance of m6A regulation in environmental health and safety (EHS) assessment: MWCNTs induced pulmonary toxicity through m6A modifications of mitophagy-related genes Nano Today 2022/9/21
Cerebral Microvascular Injury Induced by Lag3-Dependent α-Synuclein Fibril Endocytosis Exacerbates Cognitive Impairment in a Mouse Model of α-Synucleinopathies Advanced Science 2023/6/28
ID1 expressing macrophages support cancer cell stemness and limit CD8+ T cell infiltration in colorectal cancer Nature Communications 2023/11/23
[PDF] HNEAP Regulates Necroptosis of Cardiomyocytes by Suppressing the m5C Methylation of Atf7 mRNA Advanced Science 2023/10/23
FOXP1 controls mesenchymal stem cell commitment and senescence during skeletal aging The Journal of Clinical Investigation 2017/2/27
miR-410 induces both epithelial–mesenchymal transition and radioresistance through activation of the PI3K/mTOR pathway in non-small cell lung cancer Signal Transduction and Targeted Therapy 2020/1/13
CPAL, as a New Mediator of Cardiomyocyte Metabolic Alterations and Pyroptosis, Regulates Myocardial Infarction Injury in Mice Engineering 2022/10/14
SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating the CK2-mediated MAPK/ERK and PI3K/AKT pathways Experimental & Molecular Medicine 2023/8/1


Validation data

No data found


Associated products and services


Products & Service Products & Service Information
AAV Packaging service Detail
Promise-ORF™ viral CDNA library Detail
Plasmid DNA Rapid Preparation Service Detail